GLP-1 수용체 작용제 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 용도별, 투여 경로별, 지역별, 부문별 예측(2025-2030년)

GLP-1 Receptor Agonist Market Growth & Trends:

The global GLP-1 receptor agonist market size is expected to reach USD 156.71 billion by 2030, expanding at a CAGR of 17.46% from 2025 to 2030, according to a new report by Grand View Research, Inc. The strong product pipeline and formulation advancements are driving the market. In addition, novel innovative products are booming the market. In September 2019, Rybelsus, the first and only oral GLP-1 analog was approved by the U.S.FDA for improving the glycemic control in type-2 diabetes patients. It is a semaglutide-based product developed by Novo Nordisk, which is currently under review by European Medicines Agency (EMA) and Pharmaceuticals and Medical Devices Agency (PMDA). After receiving the approval, the market may witness significant growth over the forecast period.

Furthermore, pharmaceutical companies are focusing on research collaborations for developing new GLP-1 products. For instance, in September 2018, Eli Lilly and Company entered into a license agreement with Chugai Pharmaceutical Co., Ltd for OWL833. OWL833 is Chugai's proprietary oral GLP-1 agonist candidate and as per the agreement Eli Lilly will obtain global commercialization and development rights.

The companies are currently aiming on geographical expansion for increasing the sales output. Novo Nordisk is expanding its business by investing in the manufacturing unit located in North Carolina. The company holds around 50.0% of the market share of GLP-1 receptor agonists and is expected to dominate the market over the forecast period. Furthermore, in July 2018, Sanofi invested about USD 74.1 million in China for establishing an R&D hub to enhance its global reach.

The companies are also focusing on getting approval for other indications like obesity and major adverse cardiovascular events by authorities like the U.S.FDA, EMEA, and others for the existing products to increase their life cycle. For instance, in January 2020, Novo Nordisk received the U.S. FDA approval for Ozempic for Major Adverse Cardiovascular Events (MACE) in type 2 diabetes patients.

GLP-1 Receptor Agonist Market Report Highlights:

• The ozempic segment dominated the market and accounted for a share of 34.17% in 2024. Ozempic is a brand-name U.S. FDA-approved prescription drug used to treat adults with type 2 diabetes.
• Zepbound is expected to grow at a significant CAGR from 2025 to 2030. This growth can be attributed to its worldwide approval of a drug and high demand due to its high efficacy and tolerability.
• The type 2 diabetes mellitus segment dominated the market in 2024 and is expected to grow at a CAGR of 17.06% over the forecast period.
• The parenteral segment held the largest share in 2024 and is expected to grow at a CAGR of 17.42% from 2025 to 2030.
• The hospital pharmacies segment held the largest share of 55.09% in 2024. The growth of hospital pharmacies has facilitated the integration of several healthcare components, increased inpatient visits for diabetes and obesity consultations, and improved customer convenience in acquiring GLP-1 medications.
• North America GLP-1 receptor agonist market accounted for a 77.72% share in 2024. Established brands including liraglutide (Victoza), dulaglutide (Trulicity), exenatide (Byetta/Bydureon), and semaglutide (Ozempic) dominate the GLP-1 receptor agonist market in North America.
• Asia Pacific GLP-1 receptor agonists market is anticipated to witness the fastest growth in the global market. The region's growing healthcare sector, sizable target population, and high unmet clinical needs are some factors projected to provide significant growth potential.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Application
  • 1.2.3. Route of Administration
  • 1.2.4. Distribution Channel
  • 1.2.5. Regional scope
  • 1.2.6. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product and Application Outlook
  • 2.2.2. Route of Administration and Distribution Channel outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. GLP-1 Receptor Agonist Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing prevalence of chronic diseases such as diabetes and obesity
    • 3.2.1.2. Increasing R&D activities for developing novel therapeutics
    • 3.2.1.3. Formulation advancements of oral GLP-1 receptor agonists
    • 3.2.1.4. Increasing awareness about diagnosis and treatment options for diabetes
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Product failure
    • 3.2.2.2. Patent expiry of blockbuster drugs during the forecast period
• 3.3. GLP-1 Receptor Agonist Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
• 3.4. Pricing Analysis
• 3.5. Pipeline Analysis
• 3.6. Patent Expiry Analysis

Chapter 4. GLP-1 Receptor Agonist Market: Product Estimates & Trend Analysis

• 4.1. Global GLP-1 Receptor Agonist Market: Product Dashboard
• 4.2. Global GLP-1 Receptor Agonist Market: Product Movement Analysis
• 4.3. Ozempic
  • 4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.4. Rybelsus
  • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Trulicity
  • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Saxenda
  • 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Wegovy
  • 4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.8. Victoza
  • 4.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.9. Mounjaro
  • 4.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.10. Zepbound
  • 4.10.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.11. Others
  • 4.11.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. GLP-1 Receptor Agonist Market: Application Estimates & Trend Analysis

• 5.1. Global GLP-1 Receptor Agonist Market: Application Dashboard
• 5.2. Global GLP-1 Receptor Agonist Market: Application Movement Analysis
• 5.3. Type 2 Diabetes Mellitus
  • 5.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.4. Obesity
  • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. GLP-1 Receptor Agonist Market: Route of Administration Estimates & Trend Analysis

• 6.1. Global GLP-1 Receptor Agonist Market: Route of Administration Dashboard
• 6.2. Global GLP-1 Receptor Agonist Market: Route of Administration Movement Analysis
• 6.3. Parenteral
  • 6.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.4. Oral
  • 6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. GLP-1 Receptor Agonist Market: Distribution Channel Estimates & Trend Analysis

• 7.1. Global GLP-1 Receptor Agonist Market: Distribution Channel Dashboard
• 7.2. Global GLP-1 Receptor Agonist Market: Distribution Channel Movement Analysis
• 7.3. Hospital Pharmacies
  • 7.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 7.4. Retail Pharmacies
  • 7.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Online Pharmacies
  • 7.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. GLP-1 Receptor Agonist Market: Regional Estimates & Trend Analysis By Product, Application, Route of Administration, and Distribution Channel

• 8.1. Regional Dashboard
• 8.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030
• 8.3. North America
  • 8.3.1. U.S.
    • 8.3.1.1. Key country dynamics
    • 8.3.1.2. Regulatory framework/ reimbursement structure
    • 8.3.1.3. Competitive scenario
    • 8.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.3.2. Canada
    • 8.3.2.1. Key country dynamics
    • 8.3.2.2. Regulatory framework/ reimbursement structure
    • 8.3.2.3. Competitive scenario
    • 8.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.3.3. Mexico
    • 8.3.3.1. Key country dynamics
    • 8.3.3.2. Regulatory framework/ reimbursement structure
    • 8.3.3.3. Competitive scenario
    • 8.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 8.4. Europe
  • 8.4.1. UK
    • 8.4.1.1. Key country dynamics
    • 8.4.1.2. Regulatory framework/ reimbursement structure
    • 8.4.1.3. Competitive scenario
    • 8.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.2. Germany
    • 8.4.2.1. Key country dynamics
    • 8.4.2.2. Regulatory framework/ reimbursement structure
    • 8.4.2.3. Competitive scenario
    • 8.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.3. France
    • 8.4.3.1. Key country dynamics
    • 8.4.3.2. Regulatory framework/ reimbursement structure
    • 8.4.3.3. Competitive scenario
    • 8.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.4. Italy
    • 8.4.4.1. Key country dynamics
    • 8.4.4.2. Regulatory framework/ reimbursement structure
    • 8.4.4.3. Competitive scenario
    • 8.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.5. Spain
    • 8.4.5.1. Key country dynamics
    • 8.4.5.2. Regulatory framework/ reimbursement structure
    • 8.4.5.3. Competitive scenario
    • 8.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.6. Denmark
    • 8.4.6.1. Key country dynamics
    • 8.4.6.2. Regulatory framework/ reimbursement structure
    • 8.4.6.3. Competitive scenario
    • 8.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.7. Sweden
    • 8.4.7.1. Key country dynamics
    • 8.4.7.2. Regulatory framework/ reimbursement structure
    • 8.4.7.3. Competitive scenario
    • 8.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.8. Norway
    • 8.4.8.1. Key country dynamics
    • 8.4.8.2. Regulatory framework/ reimbursement structure
    • 8.4.8.3. Competitive scenario
    • 8.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. Japan
    • 8.5.1.1. Key country dynamics
    • 8.5.1.2. Regulatory framework/ reimbursement structure
    • 8.5.1.3. Competitive scenario
    • 8.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.2. China
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework/ reimbursement structure
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.3. India
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework/ reimbursement structure
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.4. Australia
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Regulatory framework/ reimbursement structure
    • 8.5.4.3. Competitive scenario
    • 8.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.5. South Korea
    • 8.5.5.1. Key country dynamics
    • 8.5.5.2. Regulatory framework/ reimbursement structure
    • 8.5.5.3. Competitive scenario
    • 8.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.6. Thailand
    • 8.5.6.1. Key country dynamics
    • 8.5.6.2. Regulatory framework/ reimbursement structure
    • 8.5.6.3. Competitive scenario
    • 8.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 8.6. Latin America
  • 8.6.1. Brazil
    • 8.6.1.1. Key country dynamics
    • 8.6.1.2. Regulatory framework/ reimbursement structure
    • 8.6.1.3. Competitive scenario
    • 8.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.2. Argentina
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework/ reimbursement structure
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 8.7. MEA
  • 8.7.1. South Africa
    • 8.7.1.1. Key country dynamics
    • 8.7.1.2. Regulatory framework/ reimbursement structure
    • 8.7.1.3. Competitive scenario
    • 8.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.2. Saudi Arabia
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework/ reimbursement structure
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.3. UAE
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory framework/ reimbursement structure
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.4. Kuwait
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Regulatory framework/ reimbursement structure
    • 8.7.4.3. Competitive scenario
    • 8.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company/Competition Categorization
• 9.2. Participant Overview
• 9.3. Financial Overview
• 9.4. Product Benchmarking
• 9.5. Company Market Share Analysis, 2024
• 9.6. Strategy Mapping
• 9.7. Company Profiles
  • 9.7.1. Eli Lilly and Company.
    • 9.7.1.1. Company overview
    • 9.7.1.2. Financial performance
    • 9.7.1.3. benchmarking
    • 9.7.1.4. Strategic initiatives
  • 9.7.2. Sanofi
    • 9.7.2.1. Company overview
    • 9.7.2.2. Financial performance
    • 9.7.2.3. benchmarking
    • 9.7.2.4. Strategic initiatives
  • 9.7.3. Novo Nordisk A/S
    • 9.7.3.1. Company overview
    • 9.7.3.2. Financial performance
    • 9.7.3.3. benchmarking
    • 9.7.3.4. Strategic initiatives
    • 9.7.3.5.
  • 9.7.4. AstraZeneca.
    • 9.7.4.1. Company overview
    • 9.7.4.2. Financial performance
    • 9.7.4.3. benchmarking
    • 9.7.4.4. Strategic initiatives